Adtralza 300 mg Tralokinumab Pre-filled Syringes

Adtralza 300 mg (Tralokinumab) Pre-filled Syringes — Complete Guide for Atopic Dermatitis

Key Facts Table

Short Description

Adtralza (tralokinumab) is a targeted biologic therapy that neutralizes IL-13, reducing skin inflammation, itch, and lesion severity in atopic dermatitis that has not responded adequately to topical therapy. It can be used with or without topical corticosteroids.

Table of Contents

• Introduction
• What Is Adtralza?
• How Does It Work?
• Main Benefits
• Real Use Cases
• Who Is It Best For?
• Who Should Avoid It?
• How to Use Correctly
• Best Time to Use
• Common Questions Users Ask
• Expected Results Timeline
• Common Mistakes
• Myths vs Facts
• Drug Interactions
• Contraindications
• Required Tests
• What to Eat With It
• Effect on Other Medications
• When To See a Doctor
• NSL Expert Tip
• Conversational FAQ
• Conclusion

Introduction

For adults living with widespread, relentlessly itchy eczema, creams alone often stop working. Adtralza belongs to the newer generation of biologic medicines designed for exactly this stage: instead of suppressing the whole immune system, it switches off one specific inflammatory signal — IL-13 — that sits at the center of atopic dermatitis. The result for many patients is calmer skin, less itching, and better sleep.

What Is Adtralza?

Adtralza is a fully human monoclonal antibody (tralokinumab) developed by LEO Pharma. Each dose consists of two pre-filled 150 mg syringes injected under the skin. It is approved in Europe for moderate-to-severe atopic dermatitis in adults and adolescents from 12 years who are candidates for systemic therapy.

How Does It Work?

Atopic dermatitis skin is flooded with interleukin-13, a signaling protein that drives inflammation, weakens the skin barrier, and triggers itch. Tralokinumab binds IL-13 directly and prevents it from docking onto its receptors. With the signal blocked, inflammation cools down, the barrier begins to repair, and the itch-scratch cycle weakens.

Main Benefits

• Targeted action on IL-13 without broad immunosuppression.
• Meaningful reduction in eczema extent and severity (EASI scores) in clinical trials.
• Noticeable itch relief, which improves sleep and daily life.
• Can be combined with topical corticosteroids when needed.
• Convenient every-two-weeks maintenance schedule; some well-controlled patients may move to every four weeks per their doctor.
• Suitable for long-term continuous use under specialist care.

Real Use Cases

• An adult whose eczema covers large body areas despite potent topical steroids and moisturizers.
• A patient cycling through repeated oral corticosteroid courses who needs a safer long-term option.
• An adolescent (12+) with severe eczema affecting school and sleep.
• A patient who could not tolerate ciclosporin or for whom it is contraindicated.

Who Is It Best For?

Adults and adolescents (12 years and older) with moderate-to-severe atopic dermatitis that is inadequately controlled by topical treatment, who are candidates for systemic therapy as judged by a dermatologist.

Who Should Avoid It?

• Anyone with known hypersensitivity to tralokinumab or its excipients.
• Patients with an active serious infection until it is treated.
• Patients with untreated parasitic (helminth) infections — these must be cleared first.
• Live vaccines should not be given during treatment; vaccination plans need review before starting.
• Pregnant or breastfeeding women only after a specialist risk–benefit assessment.

How to Use Correctly

1. Initial loading dose: 600 mg (four 150 mg syringes) given at the start of treatment.
2. Maintenance: 300 mg (two syringes) every two weeks, injected subcutaneously in the thigh or abdomen (avoid 5 cm around the navel).
3. Take the syringes out of the refrigerator and let them reach room temperature before injecting, as instructed in the leaflet.
4. Inject the two syringes at different sites; rotate sites at every session.
5. Do not shake the syringes; do not use if the liquid is cloudy or discolored.
6. Continue eye-care follow-up if you develop redness or irritation — conjunctivitis is a known side effect.

Best Time to Use

Any time of day works — consistency of the two-week interval matters more than the hour. Setting a fixed calendar day (e.g., every other Saturday) prevents missed doses. If a dose is missed, inject as soon as possible, then return to the regular schedule.

Common Questions Users Ask

Is Adtralza a steroid? No. It is a biologic antibody that blocks one inflammatory signal; it does not carry corticosteroid side effects.

Can I still use my creams? Yes — topical corticosteroids can be used alongside Adtralza when your doctor advises.

Does it cure eczema? No biologic cures atopic dermatitis; Adtralza controls it for as long as treatment continues.

Expected Results Timeline

Common Mistakes

• Injecting cold syringes straight from the fridge — painful and unnecessary.
• Stopping treatment as soon as the skin clears, which usually brings the flare back.
• Skipping the loading dose or stretching intervals without medical approval.
• Ignoring persistent red or sticky eyes instead of reporting them.
• Receiving a live vaccine mid-treatment without telling the prescriber.

Myths vs Facts

Drug Interactions

• Live vaccines (e.g., MMR, yellow fever): avoid during treatment; complete them beforehand per your doctor.
• Inactivated vaccines (e.g., influenza, COVID-19): generally acceptable — confirm timing with the prescriber.
• No significant cytochrome-based interactions are expected, but always disclose all medicines, including immunosuppressants, before starting.

Contraindications

Hypersensitivity to tralokinumab or any excipient. Treatment should not start during an active serious infection or untreated helminth infection, and live vaccines are not to be administered concurrently.

Required Tests

• Screening for active infections before starting, per specialist judgment.
• Review and completion of the vaccination schedule before the first dose.
• Parasite screening in patients from or traveling to endemic areas when indicated.
• Routine dermatology follow-up (EASI/itch scoring) to document response by week 16.

What to Eat With It

No food restrictions apply to Adtralza itself. Supporting skin health helps the treatment: adequate protein, omega-3 sources (fish, flaxseed), and good hydration. If you have confirmed food triggers identified with your doctor or allergist, keep avoiding them — but do not start elimination diets on your own, as unnecessary restriction harms more than it helps.

Effect on Other Medications

Tralokinumab does not meaningfully alter how the liver processes other drugs. The practical considerations are vaccine timing (above) and coordination when transitioning from other systemic eczema therapies (ciclosporin, methotrexate, oral steroids) — your dermatologist plans the overlap or washout. Do not layer systemic immunotherapies on your own.

When To See a Doctor

• Eye redness, itching, discharge, or vision changes.
• Signs of infection: fever, persistent cough, skin becoming hot, swollen, and painful.
• Any allergic reaction: facial swelling, breathing difficulty, widespread hives.
• No meaningful improvement by week 16.
• Before any planned vaccination, surgery, or pregnancy.

NSL Expert Tip

Conversational FAQ

How is Adtralza different from Dupixent?
Dupilumab blocks IL-4 and IL-13 signaling; tralokinumab targets IL-13 alone. Both are injectable biologics for atopic dermatitis — the choice is a specialist decision based on your profile.

Can the interval be extended?
Some patients with clear or almost-clear skin at week 16 may move to 300 mg every four weeks — only by the prescriber’s decision.

Is it safe for teenagers?
It is approved from age 12 for moderate-to-severe atopic dermatitis under specialist care.

Do I stop my moisturizers?
No — daily emollients remain the foundation of eczema care alongside any biologic.

What if I get pregnant during treatment?
Inform your doctor immediately; continuing or pausing is an individualized specialist decision.

Conclusion

Adtralza 300 mg offers precise, steroid-free control of moderate-to-severe atopic dermatitis by neutralizing IL-13 at the source. With correct injection technique, a consistent two-week schedule, vaccine planning, and attention to eye symptoms, most suitable patients reach a level of skin control that topical therapy alone could not deliver. It is a specialist-supervised, prescription-only biologic from the first dose onward.